Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population

• Title in English: Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic
• Authors: SKŘIČKOVÁ Jana; KEILOVÁ Jana; JANASKOVÁ Tereza; KOLEK Vítězslav; TOMÍŠKOVÁ Marcela; BABIČKOVÁ Lenka; KADLEC Bohdan; GRYGARKOVÁ Yvona; BARTOŠ Jiří; CHALUPA Jan; TŘASOŇ Tomáš; GRUNA Jiří; ŠVECOVÁ Jana; COUPKOVÁ Helena
• Year of publication: 2011
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: Lung cancer is the leading cause of cancer mortality in the Czech Republic. Approximately 80% of cases are NSCLC and 65% of patients have advanced disease at the time of diagnosis. For patients with advanced NSCLC and preserved functional status, the standard therapy is a double agent platinum-based chemotherapy. Most patients who receive first-line chemotherapy experience disease progression within 3 to 6 months of initiating therapy and the median survival time observed is 8 to 10 months. In this situation, there is a need to find effective therapeutic regimen with an administration as simple as possible and the most favorable toxicity profile. The purpose of this trial was to evaluate the activity and feasibility of CBDCA together with NVBiv and NVBo.